Results 51 to 60 of about 4,990 (167)
From Desferrioxamine B Umpolung to an Enantiopure Bifunctional Chelator for 89Zr‐immunoPET
Chemistry – A European Journal, Volume 31, Issue 34, June 17, 2025.Functional group transformations were performed at the pendent amine residue of desferrioxamine B (DFO), the commercial siderophore used in various medical applications, including iron decorporation, antibiotic development, and molecular imaging.
Laurie Zujew +2 more
wiley +1 more source
Nature Communications, 2018 One of the major obstacles in nanoparticle-based therapy is to achieve tumour targeting, limiting non-specific accumulation of the nanoparticles. Here the authors propose the conjugation of anti-HER2 scFv fragments to the silica nanoparticles, increasing
Feng Chen +18 more
doaj +1 more source
ToxinsSarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato +3 more
doaj +1 more source
Antibodies, 2018 Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well as macrophage-associated human diseases.
Zhiwei Hu
doaj +1 more source
Beyond Conventional Approaches: The Revolutionary Role of Nanoparticles in Breast Cancer
MedComm – Biomaterials and Applications, Volume 4, Issue 2, June 2025.This review explores integrated approach of nanotechnology to breast cancer diagnosis and treatment. We highlight imaging techniques for tumor detection and biomarker analysis in biological samples for early diagnosis. Advanced therapies, including targeted drug delivery and antibody‐drug conjugates, enable precise medication transport to cancer cells,
Mohan Liu +7 more
wiley +1 more source
Individually Specified Drug Immunoconjugates in Cancer Treatment
The International Journal of Biological Markers, 1989 Forty-three patients with disseminated refractory malignancies each received an individually-specified combination of either Adriamycin (24 patients) or mitomycin-C (19 patients) conjugated murine monoclonal antibodies. Tumors were typed using a panel of
R.K. Oldham +6 more
doaj +1 more source
Nature Communications, 2020 An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Anna Galstyan +20 more
doaj +1 more source
Advanced Science, Volume 12, Issue 19, May 22, 2025.A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang +16 more
wiley +1 more source
Site‐Specific Modification of Native IgGs with Flexible Drug‐Load
ChemBioChem, Volume 26, Issue 8, April 14, 2025.ADC generation from native IgG: using short, positively charged peptides like RAK enables the direct modification of IgG at the glutamine Q295 without the need for engineering. Using azide‐ and thiol‐group containing RAK, the generation of ADCs with different drug‐to‐antibody ratios (DARs) is demonstrated and their properties analyzed in‐vitro and in ...
Jöri E. Wehrmüller +7 more
wiley +1 more source
Cancer, Volume 131, Issue 7, 1 April 2025.Abstract Background Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited. Methods The INO‐CD22 study is a multicenter retrospective cohort study of adult patients with relapsed/refractory B‐ALL treated with IO in 24 Italian centers from 2014 to 2019, with ...
Cristina Papayannidis +32 more
wiley +1 more source